OncoLize

Executive Summary

OncoLize is a Netherlands-based biotechnology company pioneering localized, slow-release drug delivery systems for oncology. Founded in 2017, the company focuses on improving tumor eradication while minimizing systemic side effects by directly delivering therapeutics to the tumor microenvironment. Its proprietary platform enables sustained release of chemotherapeutics or immunomodulators, potentially enhancing efficacy and reducing dosing frequency. OncoLize is initially targeting pancreatic cancer, one of the most aggressive and treatment-resistant malignancies, where localized delivery could overcome poor drug penetration and high toxicity. The company is also exploring applications in other solid tumors with high unmet needs. Currently in the pre-clinical stage, OncoLize is preparing for first-in-human trials and has operations in Maastricht, Leiden, and Dublin. With a strong scientific rationale and a clear unmet need, OncoLize represents a promising approach in the oncology drug delivery space. However, as a pre-revenue biotech with no disclosed funding rounds, the company faces significant development and regulatory risks. Its success hinges on successful IND filing, clinical trial execution, and eventual commercialization.

Upcoming Catalysts (preview)

• Q4 2026IND/CTA submission for pancreatic cancer program40% success
• Q1 2027First-in-human trial initiation in pancreatic cancer30% success
• Q3 2026Preclinical data publication or presentation at a major conference70% success